Merck & Co., Inc.(MRK) Stock Research - Grey Stern Research

Merck & Co., Inc. (MRK) Stock Analysis

$101.85 (1.23%)

MRK Financial Performance


Use the table below to view Merck & Co., Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $101.88 -
52 Week Low $98.60 -
52 Week High $134.63 -
Market Cap $258.2 Billion 4/8
Gross Margin 81% 2/8
Profit Margin 34% 1/8
EBITDA margin 43% 1/8
Q2 - 2024 Revenue $16.1 Billion 3/8
Q2 - 2024 Earnings $5.5 Billion 1/8
Q2 - 2024 Free Cash Flow $4.8 Billion 3/8
Trailing 4 Quarters Revenue $62.5 Billion 2/8
Trailing 4 Quarters Earnings $13.7 Billion 2/8
Quarterly Earnings Growth 191% 3/8
Annual Earnings Growth 452% 1/8
Quarterly Revenue Growth 7% 5/8
Annual Revenue Growth 7% 5/8
Cash On Hand $11.3 Billion 2/8
Short Term Debt $3.1 Billion 3/8
Long Term Debt $34.7 Billion 5/8

Merck & Co., Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Merck & Co., Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 18.80 7/8
PS 4.13 5/8
PB 5.92 5/8
PC 22.76 4/8
Liabilities to Equity 1.58 5/8
ROA 0.12 1/8
ROE 0.32 4/8
Current Ratio 1.63 2/8
Quick Ratio 0.17 2/8
Long Term Debt to Equity 0.80 5/8
Debt to Equity 0.87 5/8
Burn Rate -3.44 8/8
Cash to Cap 0.04 3/8
CCR 0.89 6/8
EV to EBITDA 41.45 6/8
EV to Revenue 4.56 4/8

Company Details

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CEO: Mr. Kenneth Frazier

Website: https://www.merck.com

Address: 2000 Galloping Hill Rd Kenilworth, NEW JERSEY

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—General

Merck & Co., Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Merck & Co., Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $144.8 Billion
Bristol-Myers Squibb Company BMY $119.0 Billion
Gilead Sciences, Inc. GILD $115.3 Billion
AbbVie Inc. ABBV $320.7 Billion
Johnson & Johnson JNJ $366.8 Billion
Amgen Inc. AMGN $149.6 Billion
Eli Lilly and Company LLY $772.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MRK Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 16.7 Billion $3.2 Billion
Q2 2024 $ 16.1 Billion $5.5 Billion
Q1 2024 $ 15.8 Billion $4.8 Billion
Q4 2023 $ 14.6 Billion -$1.2 Billion
Q3 2023 $ 16.0 Billion $4.7 Billion
Q2 2023 $ 15.0 Billion -$6.0 Billion
Q1 2023 $ 14.5 Billion $2.8 Billion
Q4 2022 $ 13.8 Billion $3.0 Billion

View All

MRK Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $11.3 Billion $112.6 Billion $37.8 Billion $43.6 Billion
Q1 2024 $5.7 Billion $105.8 Billion $34.2 Billion $40.4 Billion
Q4 2023 $8.8 Billion $0 $0 $41.3 Billion
Q3 2023 $8.6 Billion $97.2 Billion $34.9 Billion $41.3 Billion
Q2 2023 $5.7 Billion $95.3 Billion $36.9 Billion $38.7 Billion
Q1 2023 $9.7 Billion $107.8 Billion $30.7 Billion $46.8 Billion
Q4 2022 $12.7 Billion $109.2 Billion $30.7 Billion $46.0 Billion
Q3 2022 $11.1 Billion $97.5 Billion $30.4 Billion $44.5 Billion

View All

MRK Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $4.8 Billion -$791.0 Million $5.7 Billion
Q1 2024 $2.2 Billion -$861.0 Million -$1.2 Billion
Q4 2023 $0 $0 $0
Q3 2023 $0 $0 $0
Q2 2023 $0 $0 $0
Q1 2023 $332.0 Million -$1.0 Billion -$3.0 Billion
Q4 2022 $3.3 Billion -$1.1 Billion $1.5 Billion
Q3 2022 $4.5 Billion -$1.1 Billion $1.5 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions